Retrospective analysis of adverse drug reactions of bevacizumab biosimilar and original drug in our hospital

DING Nianyang; LI Li; FANG Panqi; XU Silu; ZHAO Min; YAN Dan

doi:10.6039/j.issn.1001-0408.2024.04.17

您当前的位置：

首页 >

文章列表页 >

Retrospective analysis of adverse drug reactions of bevacizumab biosimilar and original drug in our hospital

更新时间：2024-02-23

- Retrospective analysis of adverse drug reactions of bevacizumab biosimilar and original drug in our hospital
- ZHONGGUO YAOFANG Vol. 35, Issue 4, Pages: 472-475(2024)
- 作者机构：
  
  1.江苏省肿瘤医院/南京医科大学附属肿瘤医院/江苏省肿瘤防治研究所药学部，南京　210009
  2.南京市食品药品监督检验院，南京　211198
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2024.04.17
  CLC： R969.3
- Published：29 February 2024，
  
  Received：21 August 2023，
  
  Revised：29 January 2024，
扫描看全文
丁年羊,李莉,方攀奇等.我院贝伐珠单抗生物类似药与原研药相关不良反应回顾性分析 ^Δ[J].中国药房,2024,35(04):472-475.

DING Nianyang,LI Li,FANG Panqi,et al.Retrospective analysis of adverse drug reactions of bevacizumab biosimilar and original drug in our hospital[J].ZHONGGUO YAOFANG,2024,35(04):472-475.
丁年羊,李莉,方攀奇等.我院贝伐珠单抗生物类似药与原研药相关不良反应回顾性分析 ^Δ[J].中国药房,2024,35(04):472-475. DOI： 10.6039/j.issn.1001-0408.2024.04.17.

DING Nianyang,LI Li,FANG Panqi,et al.Retrospective analysis of adverse drug reactions of bevacizumab biosimilar and original drug in our hospital[J].ZHONGGUO YAOFANG,2024,35(04):472-475. DOI： 10.6039/j.issn.1001-0408.2024.04.17.

摘要

目的

分析某院贝伐珠单抗生物类似药与原研药相关药物不良反应（ADR）的发生情况，为临床合理用药提供数据支持。

方法

对江苏省肿瘤医院2022年1－12月上报的贝伐珠单抗生物类似药和原研药相关ADR报告进行回顾性分析。

结果

我院使用贝伐珠单抗的患者共6 818人次，上报ADR报告136份，贝伐珠单抗生物类似药的ADR发生率显著高于原研药（2.18% vs. 0.71%，

＝0.004）。ADR报告中，治疗方案以贝伐珠单抗与其他肿瘤治疗药物的联合治疗方案为主（129人次）；痊愈和好转的患者有118人次；一般ADR报告108份，严重ADR报告28份；ADR主要累及系统/器官以心血管系统为主，贝伐珠单抗生物类似药与原研药引起的高血压/血压升高、白细胞/血小板降低、腹泻和发热发生率比较，差异均无统计学意义。

结论

贝伐珠单抗生物类似药的相关ADR发生率明显高于原研药，但ADR临床表现无明显差异，临床医生可以根据患者及其家属意愿选择使用。

Abstract

OBJECTIVE

To analyze the occurrence of adverse drug reactions （ADR） between bevacizumab biosimilars and original drugs， and to provide data support for rational use of drugs in clinical.

METHODS

ADR reports of bevacizumab biosimilars and original drugs reported by Jiangsu Cancer Hospital from January to December 2022 were retrospectively analyzed.

RESULTS

A total of 6 818 patients were treated with bevacizumab， and 136 ADR patients were reported. The incidence of ADR caused by bevacizumab biosimilars was higher than original drugs （2.18% vs. 0.71%，

＝0.004）. In ADR reports， the main treatment plan was bevacizumab combined with other tumor drugs （129 patients）； 118 patients were cured and improved； there were 108 general reports and 28 serious reports； the main system/organ involved in ADR was the cardiovascular system； there were no statistical significance in the incidence rates of hypertension/blood pressure increase， leukocyte/platelet decrease， diarrhea and fever caused by bevacizumab biosimilars and original drugs.

CONCLUSIONS

The incidence of ADR related to bevacizumab biosimilars is significantly higher than that of the original drugs， but there is no significant difference in the clinical manifestation of ADR. Clinicians can use bevacizumab biosimilars or original drugs based on the willingness of patients and their families.

关键词

贝伐珠单抗生物类似药原研药药物不良反应合理使用

Keywords

biosimilarsoriginal drugsadverse drug reactionsreasonable use

references

国家卫生健康委办公厅.关于印发新型抗肿瘤药物临床应用指导原则（2023年版）的通知[EB/OL].（2023-01-02）[2024-01-29]. http：//www.nhc.gov.cn/yzygj/s7659/202401/48be6030a029446c93b852bfd4a5fdf6.shtmlhttp://www.nhc.gov.cn/yzygj/s7659/202401/48be6030a029446c93b852bfd4a5fdf6.shtml.

Office of the National Health Commission. Notice on the issuance of the guidelines for the clinical application of new anti-tumor drugs：2023 edition[EB/OL].（2023-01-02）[2024-01-29]. http：//www.nhc.gov.cn/yzygj/s7659/202401/48be6030a02-9446c93b852bfd4a5fdf6.shtmlhttp://www.nhc.gov.cn/yzygj/s7659/202401/48be6030a02-9446c93b852bfd4a5fdf6.shtml.

张轶群，琚长斌，李芳，等. 非小细胞肺癌患者贝伐珠单抗相关不良反应临床分析[J]. 药物不良反应杂志，2022，24（5）：233-238.

ZHANG Y Q，JU C B，LI F，et al. Clinical analysis of bevacizumab-related adverse reactions in patients with non-small cell lung cancer[J]. Adverse Drug React J，2022，24（5）：233-238.

种王斌，朱金祥，刘佳. 贝伐珠单抗联合奥沙利铂+卡培他滨化疗治疗转移性结直肠癌的疗效及安全性[J]. 癌症进展，2022，20（6）：624-626，635.

CHONG W B，ZHU J X，LIU J. Efficacy and safety of bevacizumab combined with oxaliplatin + capecitabine chemotherapy in the treatment of metastatic colorectal cancer[J]. Oncol Prog，2022，20（6）：624-626，635.

任晓蕾，邢丽秋，詹轶秋，等. 北京地区贝伐珠单抗不良反应报告分析及安全性研究[J]. 中国新药杂志，2020，29（14）：1670-1674.

REN X L，XING L Q，ZHAN Y Q，et al. Analysis of adverse reaction reports of bevacizumab in Beijing area[J]. Chin J N Drugs，2020，29（14）：1670-1674.

TANYI J L，MCCANN G，HAGEMANN A R，et al. Clinical predictors of bevacizumab-associated gastrointestinal perforation[J]. Gynecol Oncol，2011，120（3）：464-469.

RICHARDSON D L，BACKES F J，HURT J D，et al. Which factors predict bowel complications in patients with recurrent epithelial ovarian cancer being treated with bevacizumab?[J]. Gynecol Oncol，2010，118（1）：47-51.

SAIF M W，ELFIKY A，SALEM R R. Gastrointestinal perforation due to bevacizumab in colorectal cancer[J]. Ann Surg Oncol，2007，14（6）：1860-1869.

HOCHSTER H S，HART L L，RAMANATHAN R K，et al. Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer：results of the TREE Study[J]. J Clin Oncol，2008，26（21）：3523-3529.

DEAN E，MIDDLETON M R，PWINT T，et al. Phase Ⅰ study to assess the safety and tolerability of olaparib in combination with bevacizumab in patients with advanced solid tumours[J]. Br J Cancer，2012，106（3）：468-474.

DEL CARMEN M G，MICHA J，SMALL L，et al. A phase Ⅱ clinical trial of pegylated liposomal doxorubicin and carboplatin plus bevacizumab in patients with platinum-sensitive recurrent ovarian，fallopian tube，or primary peritoneal cancer[J]. Gynecol Oncol，2012，126（3）：369-374.

CANNISTRA S A，MATULONIS U A，PENSON R T，et al. Phase Ⅱ study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer[J]. J Clin Oncol，2007，25（33）：5180-5186.

谢曌璐，张卿，杨雪，等. 贝伐珠单抗首次使用后出现肠梗阻1例[J]. 肿瘤药学，2021，11（3）：378-380，384.

XIE Z L，ZHANG Q，YANG X，et al. A case of intestinal obstruction after the first use of bevacizumab[J]. Anti Tumor Pharm，2021，11（3）：378-380，384.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

A meta-analysis of the effectiveness and safety of trastuzumab biosimilars versus original drugs in the treatment of HER-2 positive breast cancer

上海崇明地区3家二级综合医院2011年5月至2012 年1月抗菌药物利用分析

抗菌药物合理使用信息管理系统在抗菌药物管理中的实践

基于PEST分析模型的基本药物合理使用影响因素分析

对乙酰氨基酚制剂治疗癌痛的安全剂量

Related Author

DENG Weishang

LI Mengting

HU Jia

YANG Sensen

CHEN Jisheng

杨忠英樊洪中岳德永龚键倪寂施文琴

李玲廖赟袁波黄芳

王飞尹文强黄冬梅于倩倩魏艳陈钟鸣胡式良娄鹏宇

Related Institution

Key Specialty of Clinical Pharmacy， the First Affiliated Hospital of Guangdong Pharmaceutical University

Address：8/F,129 Daping Main Street,Yuzhong District,Chongqing 400042,P.R.China
Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号公网安备50010302001817
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰